



**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-41. (cancelled)

42. A pharmaceutical composition for the treatment of an HIV or hepatitis B viral infection comprising tipranavir and at least one antiviral active compound selected from the group consisting of 3'-deoxy-3'-fluorothymidine, 2',3'-dideoxy-3'-fluoroguanosine, or 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt or prodrug thereof.
43. The pharmaceutical composition according to claim 42, wherein the antiviral active compound is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.
44. The pharmaceutical composition according to claim 42, wherein the antiviral active compound is 2',3'-dideoxy-3'-fluoroguanosine, or a pharmaceutically acceptable salt or prodrug thereof.
45. The pharmaceutical composition according to claim 42, wherein the antiviral active compound is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt thereof.
46. The pharmaceutical composition according to claim 42, wherein tipranavir and the antiviral active compound are present in a ratio between about 1:250 to about 250:1.

47. The pharmaceutical composition according to claim 42 further comprising ritonavir.
48. The pharmaceutical composition according to claim 42 with at least one pharmaceutically acceptable carrier.
49. A method for treating an HIV or hepatitis B viral infection in an individual comprising administering tipranavir in combination or in alternation with at least one antiviral active compound selected from the group consisting of 3'-deoxy-3'-fluorothymidine, 2',3'-dideoxy-3'-fluoroguanosine, or 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt or prodrug thereof.
50. The method according to claim 49, wherein the antiviral active compound is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.
51. The method according to claim 49, wherein the antiviral active compound is 2',3'-dideoxy-3'-fluoroguanosine, or a pharmaceutically acceptable salt or prodrug thereof.
52. The method according to claim 49, wherein the antiviral active compound is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt thereof.
53. The method according to claim 49, wherein tipranavir and the antiviral active compound are administered to the individual in combination or in alternation in a ratio between about 1:250 to about 250:1.

54. The method according to claim 49, wherein tipranavir and the antiviral active compound are administered to the individual in combination or in alternation in a ratio between about 1:50 to about 50:1.
55. The method according to claim 49, wherein tipranavir is administered in combination with ritonavir and in combination or in alternation with the antiviral active compound.
56. The method according to claim 49, wherein tipranavir is administered in combination with the antiviral active compound.
57. A kit for the treatment of an HIV or hepatitis B viral infection in an individual, comprising:
- (a) a first containment containing a pharmaceutical composition comprising tipranavir and at least one pharmaceutically acceptable carrier, and
  - (b) a second containment containing a pharmaceutical composition comprising at least one antiviral active compound selected from the group consisting of 3'-deoxy-3'-fluorothymidine, 2',3'-dideoxy-3'-fluoroguanosine, or 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier.
58. The kit according to claim 57, wherein the antiviral active compound is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

59. The kit according to claim 57, wherein the antiviral active compound is 2',3'-dideoxy-3'-fluoroguanosine, or a pharmaceutically acceptable salt or prodrug thereof.
60. The kit according to claim 57, wherein the antiviral active compound is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt thereof.
61. The kit according to claim 57, further comprising a containment containing a pharmaceutical composition comprising ritonavir.